ArticleClinical pharmacology and therapeutics2026

Realizing Benefits of First-in-Class Generic Entry-The Case of SGLT2 Inhibitors.

Suhas Gondi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.